Compare OLMA & COO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLMA | COO |
|---|---|---|
| Founded | 2006 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Ophthalmic Goods |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 16.1B |
| IPO Year | 2020 | N/A |
| Metric | OLMA | COO |
|---|---|---|
| Price | $25.64 | $82.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 11 |
| Target Price | $40.50 | ★ $88.55 |
| AVG Volume (30 Days) | 2.8M | ★ 3.3M |
| Earning Date | 11-10-2025 | 12-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.87 |
| Revenue | N/A | ★ $4,092,400,000.00 |
| Revenue This Year | N/A | $6.56 |
| Revenue Next Year | N/A | $5.32 |
| P/E Ratio | ★ N/A | $44.18 |
| Revenue Growth | N/A | ★ 5.06 |
| 52 Week Low | $2.86 | $61.78 |
| 52 Week High | $36.26 | $100.24 |
| Indicator | OLMA | COO |
|---|---|---|
| Relative Strength Index (RSI) | 48.99 | 61.31 |
| Support Level | $25.85 | $81.92 |
| Resistance Level | $36.26 | $83.64 |
| Average True Range (ATR) | 2.65 | 1.50 |
| MACD | -1.32 | -0.17 |
| Stochastic Oscillator | 2.30 | 67.68 |
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.